World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 28 June 2021
Main ID:  NCT02828670
Date of registration: 23/06/2016
Prospective Registration: No
Primary sponsor: Centre Hospitalier Universitaire Dijon
Public title: Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA) TFH and AIHA
Scientific title: Role of T Follicular Helper Cells in Autoimmune Hemolytic Anemia (TFH in AIHA)
Date of first enrolment: June 7, 2016
Target sample size: 50
Recruitment status: Recruiting
URL:  https://clinicaltrials.gov/show/NCT02828670
Study type:  Observational
Study design:   
Phase: 
Countries of recruitment
France
Contacts
Name:     Sylvain AUDIA
Address: 
Telephone: 3.80.29.34.32
Email: sylvain.audia@chu-dijon.fr
Affiliation: 
Name:     Sylvain AUDIA
Address: 
Telephone: 3.80.29.34.32
Email: sylvain.audia@chu-dijon.fr
Affiliation: 
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients with a diagnosis of warm AIHA defined by

- Hemoglobin <11 g/dl

- Low haptoglobin level

- Positive direct antiglobulin test (IgG or IgG + complement)

- Reticulocyte count >120 G/L

- Patients

- naive to treatment for hemolytic anemia or a in relapse

- Older than 18 years

- Able to understand written and spoken French

- Persons who have provided written consent

Control population

- Patients who have given consent

- Patients over 18 years

- Patients with cold agglutinin disease (progressive AIHA and different treatments of
warm autoantibody AIHA) can be included as a sub-group of controls

- Patients with non-auto-immune hemolytic anemia (constitutional of enzymatic origin,
membrane-related,…) can be included as a sub-group of controls

Exclusion Criteria:

- Patients without national health insurance

- Pregnancy or breast-feeding women

- Adults under guardianship

- Patients with cancer or malignant hemopathy

- Patients with an on-going infection

- Patients treated with corticoids or immunosuppressants



Age minimum: 18 Years
Age maximum: N/A
Gender: All
Health Condition(s) or Problem(s) studied
Autoimmune Hemolytic Anemia
Intervention(s)
Biological: blood sample
Procedure: spleen sample
Primary Outcome(s)
the proportion of circulating T follicular helper lymphocytes (TFH) in patients with Autoimmune Hemolytic Anemia (AIHA) and in control subjects. [Time Frame: baseline]
the proportion of circulating TFH in patients with Autoimmune Hemolytic Anemia (AIHA), at diagnosis and after 3 months of treatment with steroids [Time Frame: through study completion, an average of 1 year]
Secondary Outcome(s)
Secondary ID(s)
AUDIA APJ 2014
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history